NCT04600986View on ClinicalTrials.gov

Repeated Doses of GnRH Agonist as Oocyte Triggering in Antagonist Protocol for Patients With Polycystic Ovary Syndrome

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 30, 2020

Primary Completion Date

June 30, 2022

Study Completion Date

September 30, 2022

Conditions
Polycystic Ovary Syndrome
Interventions
OTHER

Repeated dose of GnRH agonist

0.2 mg triptorelin plus a repeat dose of 0.1 mg 12 hours following the first dose.

Trial Locations (1)

Unknown

Royan Institute, Tehran

All Listed Sponsors
lead

Royan Institute

OTHER_GOV

NCT04600986 - Repeated Doses of GnRH Agonist as Oocyte Triggering in Antagonist Protocol for Patients With Polycystic Ovary Syndrome | Biotech Hunter | Biotech Hunter